Satellos Granted Composition of Matter Patent for Forazapadin
Key Highlights
- ➤U.S. Patent No. 12,747,245 covers forazapadin composition of matter claims
- ➤Patent protection for forazapadin extends through Sept. 6, 2044
- ➤Phase 2 FSHD study expected to begin in fourth quarter of 2026
- ➤Forazapadin continues Phase 2 DMD studies in pediatric and adult participants
Expert Statements
Frank Gleeson, Co-founder and Chief Executive Officer of Satellos
“The issuance of this composition of matter patent represents a significant advancement for Satellos and supports our long-term development and commercialization strategy for the program.”
Frank Gleeson, Co-founder and Chief Executive Officer of Satellos
“As the strongest form of patent protection for a pharmaceutical product, this patent reinforces the novelty of our approach to restoring muscle regeneration and strengthens our intellectual property (IP) estate surrounding forazapadin.”
Frank Gleeson, Co-founder and Chief Executive Officer of Satellos
“We intend to continue to build on this foundational IP as we advance forazapadin in Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD) and other degenerative muscle diseases.”
TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled “AP2 associated kinase 1 inhibitors and uses thereof.” The patent includes composition of matter claims covering forazapadin, Satellos’ lead clinical-stage drug candidate, as well as a broader class of AAK1 inhibitors and related compounds within the company's muscle regeneration platform.
The composition of matter patent provides intellectual property protection through Sept. 6, 2044. In addition, the company may be eligible for a Patent Term Extension for forazapadin following future U.S. marketing approval, potentially extending patent protection beyond the current expiration date.
Get started
Create a free account to read the full story.